参考文献/References:
[1] Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone[J]. J Hum Hypertens,2012,26(5):281-287.
[2] Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study[J]. JAMA,2000,283(14):1829-1836.
[3] Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension[J]. N Engl J Med,2000,342(19):1378-1384.
[4] Program NHBP. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure[M]. Bethesda(MD):National Heart, Lung, and Blood Institute(US),2004.
[5] Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension[J]. J Hypertens,2001,19(12):2271-2277.
[6] Muxfeldt ES, Margallo VS, Guimaraes GM, et al. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension[J]. Am J Hypertens,2014,27(8):1069-1078.
[7] Dernaika TA, Kinasewitz GT, Tawk MM. Effects of nocturnal continuous positive airway pressure therapy in patients with resistant hypertension and obstructive sleep apnea[J]. J Clin Sleep Med,2009,5(2):103-107.
[8] Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension[J]. Hypertension,2002,40(6):892-896.
[9] Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment[J]. J Hypertens,2004,22(11):2217-2226.
[10] Sang X, Jiang Y, Wang W, et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China[J]. J Hypertens,2013,31(7):1465-1471, 1471-1472.
[11] Pimenta E, Stowasser M, Gordon RD, et al. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism[J]. Chest,2013,143(4):978-983.
[12] Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension[J]. Hypertension,2007,49(4):839-845.
[13] Vaclavik J, Sedlak R, Jarkovsky J, et al. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial(ASPIRANT-EXT)[J]. Medicine(Baltimore),2014,93(27):e162.
[14] Williams B, Macdonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension(PATHWAY-2): a randomised, double-blind, crossover trial[J]. Lancet,2015,386(1008):2059-2068.
[15] Dahal K, Kunwar S, Rijal J, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies[J]. Am J Hypertens,2015,28(11):1376-1385.
[16] Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension[J]. Chest,2007,131(2):453-459.
[17] Calhoun DA, Nishizaka MK, Zaman MA, et al. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea[J]. Chest,2004,125(1):112-117.
[18] Raff H, Roarty TP. Renin, ACTH, and aldosterone during acute hypercapnia and hypoxia in conscious rats[J]. Am J Physiol,1988,254(3 Pt 2):R431-R435.
[19] 袁春华,徐劲松,宋宁燕,等. 间歇缺氧、睡眠剥夺大鼠血浆肾素、血管紧张素Ⅱ、醛固酮的含量变化[J]. 江西医药,2010, 45(2):106-108.
[20] Lykouras D, Theodoropoulos K, Sampsonas F, et al. The impact of obstructive sleep apnea syndrome on renin and aldosterone[J]. Eur Rev Med Pharmacol Sci,2015,19(21):4164-4170.
[21] Meston N, Davies R J, Mullins R, et al. Endocrine effects of nasal continuous positive airway pressure in male patients with obstructive sleep apnoea[J]. J Intern Med,2003,254(5):447-454.
[22] Lloberes P, Sampol G, Espinel E, et al. A randomized controlled study of CPAP effect on plasma aldosterone concentration in patients with resistant hypertension and obstructive sleep apnea[J]. J Hypertens,2014,32(8):1650-1657.
[23] Svatikova A, Olson LJ, Wolk R, et al. Obstructive sleep apnea and aldosterone[J]. Sleep,2009,32(12):1589-1592.
[24] Gonzaga CC, Gaddam KK, Ahmed MI, et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension[J]. J Clin Sleep Med,2010,6(4):363-368.
[25] Gaddam K, Pimenta E, Thomas SJ, et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report[J]. J Human Hypertens,2009,24(8):532-537.
[26] Shiota S, Ryan CM, Chiu KL, et al. Alterations in upper airway cross-sectional area in response to lower body positive pressure in healthy subjects[J]. Thorax,2007,62(10):868-872.
[27] White LH, Lyons OD, Yadollahi A, et al. Effect of below-the-knee compression stockings on severity of obstructive sleep apnea[J]. Sleep Med,2015,16(2):258-264.